ERBB2 and neoplasm: We recently reported that the novel investigational EGFR/HER2 kinase inhibitor TAK-285, which has anti-tumor activity and penetrates the rat blood-brain barrier, might be used for the treatment of HER2-overexpressing metastatic breast cancers [13-17].